Practice gaps. The need to examine the risks and benefits of intravenous immunoglobulin therapy in severe cutaneous adverse reactions

Arch Dermatol. 2012 Apr;148(4):545a-545. doi: 10.1001/archdermatol.2011.3156.
No abstract available

Publication types

  • Comment

MeSH terms

  • Drug Eruptions / drug therapy*
  • Eosinophilia / drug therapy*
  • Female
  • Humans
  • Immunoglobulins, Intravenous / adverse effects*
  • Male
  • Virus Activation*

Substances

  • Immunoglobulins, Intravenous